CClinicalTrials.gg
CompletedNCT00814203Updated Oct 29, 2021

A Registry of COPD Patients to be Used for Future Studies

An observational study in Chronic Obstructive Lung Disease, sponsored by Philip Diaz. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Philip Diaz · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
9
Ages
18 Years and older
Sex
All
01

Study summary

To develop a cohort of COPD participants to assist study staff in determining the most likely candidates for future studies.

Read the detailed description

To develop a cohort of COPD participants for study staff to determine the most likely candidates for future studies and to develop a repository of blood from subjects with COPD for future studies.

02

Conditions studied

03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 9 is below the median of 157 across 929 observational studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Philip Diaz is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

primary care clinic

Inclusion criteria

  • Patients who are 18 years of age and older who have been diagnosed with COPD by at least one of the following:

    • clinical history-a documented history of COPD, emphysema, or chronic bronchitis;
    • pulmonary function results (defined as an FEV1/FVC less than 0.7;
    • radiographic results (high-resolution CT findings of emphysema

Exclusion criteria

Exclusion Criteria:

  • in ability to give informed consent
  • prisoners
  • pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
9 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Chronic obstructive lung disease

    those with a condition

06

What researchers measure

Primary outcomes

  1. This is a registry protocol to determine factors contributing to the development of chronic obstructive lung disease.

Secondary outcomes

  1. To develop a repository of blood from subjects with COPD for future studies. These studies may include evaluation of biologic markers of disease severity and progression.

07

Study locations

1 site
  • The Ohio State University
    Columbus, Ohio 43210, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00814203
Lead sponsor
Philip Diaz
Responsible party
Philip Diaz (Philip Diaz M.D., Ohio State University) — Sponsor-investigator
First posted
Dec 24, 2008
Start date
Dec 2008
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Oct 29, 2021

Study contacts

Philip Diaz, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion